Table 4.
Relationship between treatment failure and the number of risk factors at 0–168 and 120–168 h in the neurokinin 1 receptor antagonist-evaluable population
| Number of risk factorsa | Treatment failure | |||||||
|---|---|---|---|---|---|---|---|---|
| Extended overall (0–168 h) | Beyond delayed (120–168 h) | |||||||
| FosNTP 235 mg | FosAPR | FosNTP 235 mg | FosAPR | |||||
| N | n (%) | N | n (%) | N | n (%) | N | n (%) | |
| 0 | 238 | 39 (16.4) | 302 | 86 (28.5) | 444 | 11 (2.5) | 279 | 16 (5.7) |
| 1 | 262 | 77 (29.4) | 91 | 44 (48.4) | 142 | 66 (46.5) | 114 | 57 (50.0) |
| 2 | 86 | 37 (43.0) | 0 | – | 0 | – | 0 | – |
| Cochran–Armitage trend test | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
Data were obtained from the full analysis set
FosNTP fosnetupitant; FosAPR fosaprepitant
aRisk factors (0–168 h, FosNTP 235 mg): drinking history 1 (no or rarely), smoking history 1 (no). Risk factors (0–168 h, FosAPR): sex (female). Risk factors (120–168 h, FosNTP 235 mg): treatment failure in 0–120 h (yes). Risk factors (120–168 h, FosAPR): treatment failure in 0–120 h (yes)